Patent ID: 6534312
Filing Date: 2003-03-18
Classification: A61K,C07K,C12N

Abstract:
A synthetic polynucleotide comprising a DNA sequence encoding HIV env protein or a fragment thereof, the DNA sequence comprising codons optimized for expression in a mammalian host, wherein said synthetic polynucleotide is selected from the group consisting of:a) V1Jns-tPA-HIVMN gp120, wherein the 5â€² end which is SEQ ID NO:4 and the 3â€² end which is SEQ ID NO:5; b) V1Jns-tPA-HIVIIIB gp120, wherein the 5â€² end which is SEQ ID NO:6 and the 3â€² end which is SEQ ID NO:7; c) V1Jns-tPA-gp160/opt C1/opt41-A and V1Jns-tPA-gp160/opt C1/opt41-B, wherein the opt C1 comprises SEQ ID NO:30, and the gp120/41 proteolytic cleavage sites is retained in the â€œBâ€  form (SEQ ID NO:33) and eliminated in the â€œAâ€  form (SEQ ID NO:32); d) V1Jns-tPA-gp160/opt all-A, V1Jns-tPA-gp160/opt all-B, V1Jns-tPA gp160/opt all-A (nonIIIB strains); V1Jns-tPA-gp160/opt all-B (nonIIIB strains), wherein the optimized codon usage is derived from opt C1 (SEQ ID NO:30), and wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32); e) V1Jns-tPA-gp143, V1Jns-tPA-gp143/mutRRE-A, and V1Jns-tPA-gp143/mutRRE-B, wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32); f) V1Jns-tPA-gp143/opt32-A and V1Jns-tPA-gp143/opt32-B, comprising a gp 32 opt sequence (SEQ ID NO:34), and wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32); g) V1Jns-tPA-gp143/SRV-1 3â€²-UTR, wherein the SRV-1 3â€² UTR comprises SEQ ID NO:35; h) V1Jns-tPA-gp143/opt C1/opt32A and V1Jns-tPA-gp143/opt C1/opt32B, wherein the optimized codon usage is derived from opt C1 (SEQ ID NO:30), and gp 32 opt (SEQ ID NO:34), and wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32); i) V1Jns-tPA-gp143/opt all-A, V1Jns-tPA-gp143/opt all-B, V1Jns-tPA-gp143/opt all-A (non IIIB strains), and V1Jns-tPA-gp143/opt all-B (non IIIB strains), wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32); and, j) V1Jns-tPA-gp143/opt32-A/glyB, V1Jns-tPA-gp143/opt32-B/glyB, V1Jns-tPA-gp143/opt C1/opt32-A/glyB, V1Jns-tPA-gp143/opt C1/opt32-B/glyB, V1Jns-tPA-gp143/opt all-A/glyB, V1Jns-tPA-gp143/opt all-B/glyB, V1Jns-tPA-gp143/opt all-A/glyB (non IIIB strains), V1Jns-tPA-gp143/opt all-B/glyB (non IIIB strains), which respectively contain gp 32 opt (SEQ ID NO:34) and/or opt C1 (SEQ ID NO:30), wherein the gp160 proteolytic cleavage site is retained in form â€œBâ€  (SEQ ID NO:33) and is eliminated in form â€œAâ€  (SEQ ID NO:32), and wherein the five carboxy-terminal amino acids of the expressed protein are NRLIKA (SEQ ID NO:27), and combinations thereof.